NVP-AUY922 (CAS 747412-49-3)
See product citations (3)
QUICK LINKS
NVP-AUY922 inhibits proliferation of various human cancer cell lines in vitro, with an average GI50 of 9 nM. The IC50 values of NVP-AUY922 fall in the range of 2 to 40 nM in these gastric cancer cell lines. IC50 value for the BEAS-2B cells is 28.49 nM. Treatment with NVP-AUY922 does not influence the expression of Hsp90, but expression of HSP70 gets elevated by NVP-AUY922 treatment. NVP-AUY922 increases the binding of HSP70 to Hsp90. NVP-AUY922 causes p23 dissociation from the Hsp90 complex and can then recruit HSP70 to the Hsp90 complex. Meanwhile, treatment with NVP-AUY922 causes decreased expression of HER-2 in NCI-N87 cells. NVP-AUY922 treatment results in binding of Hsp90 to client proteins and setting them up as targets for degradation by the proteasome. NVP-AUY922 can influence cell growth by affecting mutiple signaling pathways. In addition, treatment with the proteasome inhibitor, MG132, restores expression of thymidylate synthase, which was decreased by NVP-AUY922. NVP-AUY922 increases the expression of cleaved caspase-3 leading to apoptosis in Hsc-2 cells.
NVP-AUY922 (CAS 747412-49-3) References
- NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. | Eccles, SA., et al. 2008. Cancer Res. 68: 2850-60. PMID: 18413753
- NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models. | Jensen, MR., et al. 2008. Breast Cancer Res. 10: R33. PMID: 18430202
- Antitumor activity of NVP-AUY922, a novel heat shock protein 90 inhibitor, in human gastric cancer cells is mediated through proteasomal degradation of client proteins. | Lee, KH., et al. 2011. Cancer Sci. 102: 1388-95. PMID: 21453385
- Antitumor effect of novel HSP90 inhibitor NVP-AUY922 against oral squamous cell carcinoma. | Okui, T., et al. 2011. Anticancer Res. 31: 1197-204. PMID: 21508365
- The HSP90 inhibitor NVP-AUY922 radiosensitizes by abrogation of homologous recombination resulting in mitotic entry with unresolved DNA damage. | Zaidi, S., et al. 2012. PLoS One. 7: e35436. PMID: 22523597
- Antiproliferative effect of the HSP90 inhibitor NVP-AUY922 is determined by the expression of PTEN in esophageal cancer. | Bao, XH., et al. 2013. Oncol Rep. 29: 45-50. PMID: 23064324
- The HSP90 inhibitor NVP-AUY922 potently inhibits non-small cell lung cancer growth. | Garon, EB., et al. 2013. Mol Cancer Ther. 12: 890-900. PMID: 23493311
- Novel heat shock protein 90 inhibitor NVP-AUY922 synergizes with the histone deacetylase inhibitor PXD101 in induction of death of anaplastic thyroid carcinoma cells. | Kim, SH., et al. 2015. J Clin Endocrinol Metab. 100: E253-61. PMID: 25389633
- HSP90 inhibitor NVP-AUY922 enhances TRAIL-induced apoptosis by suppressing the JAK2-STAT3-Mcl-1 signal transduction pathway in colorectal cancer cells. | Lee, DH., et al. 2015. Cell Signal. 27: 293-305. PMID: 25446253
- Bioluminescence Imaging to Monitor the Effects of the Hsp90 Inhibitor NVP-AUY922 on NF-κB Pathway in Endometrial Cancer. | Yeramian, A., et al. 2016. Mol Imaging Biol. 18: 545-56. PMID: 26604096
- HSP90 inhibitor NVP-AUY922 induces cell apoptosis by disruption of the survivin in papillary thyroid carcinoma cells. | Liu, J., et al. 2017. Biochem Biophys Res Commun. 487: 313-319. PMID: 28412368
- NVP-AUY922, a novel HSP90 inhibitor, inhibits the progression of malignant pheochromocytoma in vitro and in vivo. | Lian, J., et al. 2017. Onco Targets Ther. 10: 2219-2226. PMID: 28458565
- The HSP90 inhibitor NVP-AUY922 inhibits growth of HER2 positive and trastuzumab-resistant breast cancer cells. | Canonici, A., et al. 2018. Invest New Drugs. 36: 581-589. PMID: 29396630
- Hsp90 Inhibitor; NVP-AUY922 in Combination with Doxorubicin Induces Apoptosis and Downregulates VEGF in MCF-7 Breast Cancer Cell Line. | Mohammadian, M., et al. 2020. Asian Pac J Cancer Prev. 21: 1773-1778. PMID: 32592377
- NVP-AUY922 alleviates radiation-induced lung injury via inhibition of autophagy-dependent ferroptosis. | Li, L., et al. 2022. Cell Death Discov. 8: 86. PMID: 35220409
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
NVP-AUY922, 5 mg | sc-364551 | 5 mg | $150.00 | |||
NVP-AUY922, 25 mg | sc-364551A | 25 mg | $263.00 | |||
NVP-AUY922, 100 mg | sc-364551B | 100 mg | $726.00 | |||
NVP-AUY922, 250 mg | sc-364551C | 250 mg | $1400.00 | |||
| US: (Out of Stock: Availability September 26, 2025) | ||||||
NVP-AUY922, 1 g | sc-364551D | 1 g | $2900.00 | |||
NVP-AUY922, 5 g | sc-364551E | 5 g | $11000.00 | |||